← Back to headlines
Novo Nordisk Receives US Approval for Higher Wegovy Dose
Novo Nordisk has received approval in the United States for a higher dose of its weight-loss medication, Wegovy, with plans to launch the new dosage in the US market in April.
19 Mar, 16:51 — 19 Mar, 18:19
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (47/100)4 sources30/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
cnbc
Center
Right3
Right (3)
wsjseeking-alphaberlingske
Far R
Geographic diversity— 2 regions9/34
US3Denmark1
Sources
Showing 3 of 4 sources
wsjHigh20d ago
Novo Nordisk’s Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval - WSJ
Novo Nordisk’s Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval WSJ
Read full article →cnbcMostly Factual20d ago
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Read full article →seeking-alphaMixed20d ago
Novo Nordisk wins U.S. approval for higher-dose Wegovy
Read full article →Coverage Timeline
First report: berlingske · 19 Mar, 16:05|Full coverage: 4 · 2h|Window: 2h
Left-leaningCenterRight-leaning
